Top

Published in:

Open Access 01-12-2014 | Research

Pre-radiotherapy FDG PET predicts radiation pneumonitis in lung cancer

Authors: Richard Castillo, Ngoc Pham, Sobiya Ansari, Dmitriy Meshkov, Sarah Castillo, Min Li, Adenike Olanrewaju, Brian Hobbs, Edward Castillo, Thomas Guerrero

Published in: Radiation Oncology | Issue 1/2014

Abstract

Background

A retrospective analysis is performed to determine if pre-treatment [¹⁸ F]-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG PET/CT) image derived parameters can predict radiation pneumonitis (RP) clinical symptoms in lung cancer patients.

Methods and Materials

We retrospectively studied 100 non-small cell lung cancer (NSCLC) patients who underwent FDG PET/CT imaging before initiation of radiotherapy (RT). Pneumonitis symptoms were evaluated using the Common Terminology Criteria for Adverse Events version 4.0 (CTCAEv4) from the consensus of 5 clinicians. Using the cumulative distribution of pre-treatment standard uptake values (SUV) within the lungs, the 80th to 95th percentile SUV values (SUV₈₀ to SUV₉₅) were determined. The effect of pre-RT FDG uptake, dose, patient and treatment characteristics on pulmonary toxicity was studied using multiple logistic regression.

Results

The study subjects were treated with 3D conformal RT (n = 23), intensity modulated RT (n = 64), and proton therapy (n = 13). Multiple logistic regression analysis demonstrated that elevated pre-RT lung FDG uptake on staging FDG PET was related to development of RP symptoms after RT. A patient of average age and V₃₀ with SUV₉₅ = 1.5 was an estimated 6.9 times more likely to develop grade ≥ 2 radiation pneumonitis when compared to a patient with SUV₉₅ = 0.5 of the same age and identical V₃₀. Receiver operating characteristic curve analysis showed the area under the curve was 0.78 (95% CI = 0.69 – 0.87). The CT imaging and dosimetry parameters were found to be poor predictors of RP symptoms.

Conclusions

The pretreatment pulmonary FDG uptake, as quantified by the SUV₉₅, predicted symptoms of RP in this study. Elevation in this pre-treatment biomarker identifies a patient group at high risk for post-treatment symptomatic RP.

Available only for authorised users

Ghafoori P, Marks LB, Vujaskovic Z, Kelsey CR: Radiation-induced lung injury. Assessment, management, and prevention. Oncology (Williston Park) 2008,22(1):37-47. discussion 52–3

Roberts CM, Foulcher E, Zaunders JJ, Bryant DH, Freund J, Cairns D, Penny R, Morgan GW, Breit SN: Radiation pneumonitis: a possible lymphocyte-mediated hypersensitivity reaction. Ann Intern Med 1993,118(9):696-700. 10.7326/0003-4819-118-9-199305010-00006CrossRefPubMed

Taghian AG, Assaad SI, Niemierko A, Kuter I, Younger J, Schoenthaler R, Roche M, Powell SN: Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst 2001,93(23):1806-11. 10.1093/jnci/93.23.1806CrossRefPubMed

Hart J, McCurdy MR, Ezhil M, Wei W, Khan M, Luo D, Munden R, Johnson V, Guerrero T: Radiation pneumonitis: Correlation of Toxicity with the Pulmonary Metabolic Radiation Response. Int J Radiat Oncol Biol Phys 2008,71(4):967-971. 10.1016/j.ijrobp.2008.04.002PubMedCentralCrossRefPubMed

McCurdy M, Wazni M, Martinez J, McAleer M, Guerrero T: Exhaled nitric oxide predicts radiation pneumonitis in esophageal and lung cancer patients receiving thoracic radiation. Radiotherapy and Oncology 2011, 101: 443-448. 10.1016/j.radonc.2011.08.035CrossRefPubMed

Rodrigues G, Lock M, D'Souza D, Yu E, Van Dyk J: Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer–a systematic review. Radiotherapy and Oncology 2004,71(2):127-138. 10.1016/j.radonc.2004.02.015CrossRefPubMed

Palma D, Senan S, Tsujino K, Barriger R, Rengan R, Moreno M, Bradley J, Kim T, Ramella S, Marks L, de Petris L, Stitt L, Rodrigues G: Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: An international individual patient data meta-analysis. Int. J. Radiation Oncology Biol. Phys. 2013,85(2):444-450. 10.1016/j.ijrobp.2012.04.043CrossRef

Allen AM, Czerminska M, Janne PA, Sugarbaker DJ, Bueno R, Harris JR, Court L, Baldini EH: Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 2006,65(3):640-5. 10.1016/j.ijrobp.2006.03.012CrossRefPubMed

Kristensen CA, Nottrup TJ, Berthelsen AK, Kjaer-Kristoffersen F, Ravn J, Sorensen JB, Engelholm SA: Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma. Radiother Oncol 2009,92(1):96-9. 10.1016/j.radonc.2009.03.011CrossRefPubMed

10.

Rice DC, Smythe WR, Liao Z, Guerrero T, Chang JY, McAleer MF, Jeter MD, Correa A, Vaporciyan AA, Liu HH, Komaki R, Forster KM, Stevens CW: Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2007,69(2):350-7. 10.1016/j.ijrobp.2007.03.011CrossRefPubMed

11.

Wang JY, Chen KY, Wang JT, Chen JH, Lin JW, Wang HC, Lee LN, Yang PC: Outcome and prognostic factors for patients with non-small-cell lung cancer and severe radiation pneumonitis. International Journal of Radiation Oncology, Biology, Physics. 2002,54(3):735-41. 10.1016/S0360-3016(02)02994-2CrossRefPubMed

12.

Kocak Z, Borst GR, Zeng J, Zhou S, Hollis DR, Zhang J, Evans ES, Folz RJ, Wong T, Kahn D, Belderbos JS, Lebesque JV, Marks LB: Prospective assessment of dosimetric/physiologic-based models for predicting radiation pneumonitis. Int J Radiat Oncol Biol Phys 2007,67(1):178-186. 10.1016/j.ijrobp.2006.09.031PubMedCentralCrossRefPubMed

13.

Bradley J, Paulus R, Komaki R, Masters G, Forster K, Schild S, Bogart J, Garces Y, Narayan S, Kavadi V, Nedzi L, Michalski J, Johnson D, MacRae R, Curran W, Choy H: A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617. J Clin Oncol 2013,31(supp):7501.

14.

Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA, Perez CA: Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999,45(2):323-9. 10.1016/S0360-3016(99)00183-2CrossRefPubMed

15.

Claude L, Perol D, Ginestet C, Falchero L, Arpin D, Vincent M, Martel I, Hominal S, Cordier JF, Carrie C: A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. Radiother Oncol 2004,71(2):175-81. 10.1016/j.radonc.2004.02.005CrossRefPubMed

16.

Rancati T, Ceresoli GL, Gagliardi G, Schipani S, Cattaneo GM: Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiother Oncol 2003,67(3):275-83. 10.1016/S0167-8140(03)00119-1CrossRefPubMed

17.

Guerrero T, Martinez J, McCurdy M, Wolski M, McAleer M: Elevation in exhaled nitric oxide predicts for radiation pneumonitis. Int. J. Radiation Oncology Biol. Phys. 2012,82(2):981-988. 10.1016/j.ijrobp.2010.08.041CrossRef

18.

Makimoto T, Tsuchiya S, Hayakawa K, Saitoh R, Mori M: Risk factors for severe radiation pneumonitis in lung cancer. Japanese Journal of Clinical Oncology. 1999,29(4):192-7. 10.1093/jjco/29.4.192CrossRefPubMed

19.

Sanuki N, Ono A, Komatsu E, Kamei N, Akamine S, Yamazaki T, Mizunoe S, Maeda T: Association of computed tomography-detected pulmonary interstitial changes with severe radiation pneumonitis for patients treated with thoracic radiotherapy. J. Radiat. Res. 2012, 53: 110-116. 10.1269/jrr.110142CrossRefPubMed

20.

Yamashita H, Kobayashi-Shibata S, Terahara A, Okuma K, Haga A, Wakui R, Ohtomo K, Nakagawa K: Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy. Oncology: Radiation; 2010. 5(32)

21.

Jones HA, Clark RJ, Rhodes CG, Schofield JB, Krausz T, Haslett C: In vivo measurement of neutrophil activity in experimental lung inflammation. Am J Respir Crit Care Med 1994,149(6):1635-1639. 10.1164/ajrccm.149.6.7516252CrossRefPubMed

22.

Chen DL, Rosenbluth DB, Mintun MA, Schuster DP: FDG-PET imaging of pulmonary inflammation in healthy volunteers after airway instillation of endotoxin. J Appl Physiol 2006,100(5):1602-1609. 10.1152/japplphysiol.01429.2005CrossRefPubMed

23.

Chen DL, Ferkol TW, Mintun MA, Pittman JE, Rosenbluth DB, Schuster DP: Quantifying pulmonary inflammation in cystic fibrosis with positron emission tomography. Am J Respir Crit Care Med 2006,173(12):1363-1369. 10.1164/rccm.200506-934OCPubMedCentralCrossRefPubMed

24.

Petit S, van Elmpt W, Oberije C, Vegt E, Dingemans A, Lambin P, Dekker A, de Ruysscher D: Fluorodeoxyglucose uptake patterns in lung before radiotherapy identify areas more susceptible to radiation -induced lung toxicity in non-small-cell lung cancer patients. J. Radiation Oncology Biol. Phys 2011,81(3):698-705. 10.1016/j.ijrobp.2010.06.016CrossRef

25.

Pan T, Mawlawi O, Nehmeh SA, Erdi YE, Luo D, Liu HH, Castillo R, Mohan R, Liao Z, Macapinlac HA: Attenuation Correction of PET Images with Respiration-Averaged CT Images in PET/CT. J Nucl Med 2005,46(9):1481-1487.PubMed

26.

Strauss LG, Conti PS: The applications of PET in clinical oncology. J Nucl Med 1991,32(4):623-648.PubMed

27.

Liao Z, Liu H, Komaki R: Target delineation for esophageal cancer. Journal of Women's Imaging 2003,5(4):177-186. 10.1097/00130747-200311000-00003CrossRef

28.

Vedam SS, Keall PJ, Kini VR, Mostafavi H, Shukla HP, Mohan R: Acquiring a four-dimensional computed tomography dataset using an external respiratory signal. Phys Med Biol 2003,48(1):45-62. 10.1088/0031-9155/48/1/304CrossRefPubMed

29.

Pan T, Lee TY, Rietzel E, Chen GT: 4D-CT imaging of a volume influenced by respiratory motion on multi-slice CT. Med Phys 2004,31(2):333-40. 10.1118/1.1639993CrossRefPubMed

30.

Osman MM, Cohade C, Nakamoto Y, Wahl RL: Respiratory motion artifacts on PET emission images obtained using CT attenuation correction on PET-CT. European journal of nuclear medicine and molecular imaging 2003,30(4):603-606. 10.1007/s00259-002-1024-xCrossRefPubMed

31.

Proschan MWM: Practical guidelines for multiplicity adjustment in clinical trials. Controlled Clinical Trials 2000, 21: 527-539. 10.1016/S0197-2456(00)00106-9CrossRefPubMed

32.

Akaike H: A new look at the statistical model identification. IEEE T Automat Contr 1974,19(6):716-723. 10.1109/TAC.1974.1100705CrossRef

33.

Nagelkerke NJD: A note on a general definition of the co efficient of determination. Biometrika 1991, 78: 691-692. 10.1093/biomet/78.3.691CrossRef

34.

DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988,44(3):837-45. 10.2307/2531595CrossRefPubMed

35.

Youden WJ: Index for rating diagnostic tests. Cancer 1950,3(1):32-35. 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3CrossRefPubMed

36.

Breiman L, Friedman JH, Olshen RA, Stone CJ: Classification and regression trees, Monterey, Calif. U.S.A.: Wadsworth, Inc.; 1984.

37.

McCulloch C, Searle S, Neuhaus J, Generalized L, Models M, 2nd ed : Hoboken. NJ: Wiley; 2008.

38.

Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986,1(8476):307-10.CrossRefPubMed

39.

de Prost N, Tucci MR, Melo MFV: Assessment of Lung Inflammation With 18 F-FDG PET During Acute Lung Injury. American Journal of Roentgenology 2010,195(2):292-300. 10.2214/AJR.10.4499PubMedCentralCrossRefPubMed

40.

Dehing-Oberije C, De Ruysscher D, van Baardwijk A, Yu S, Rao B, Lambin P: The importance of patient characteristics for the prediction of radiation-induced lung toxicity. Radiotherapy and Oncology 2009, 91: 421-426. 10.1016/j.radonc.2008.12.002CrossRefPubMed

41.

Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D' Amico TA, Demmy TL, Ganti AKP, Govindan R, Grannis FW, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong F-M, Kris MG, Krug LM, Le Q-T, Lennes IT, Martins R, O' Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ: Non-small cell lung cancer. Journal of the National Comprehensive Cancer Network. JNCCN 2010,8(7):740-801.PubMed

42.

Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A, Ravn J, Clementsen P, Høgholm A, Larsen K, Rasmussen T, Keiding S, Dirksen A, Gerke O, Skov B, Steffensen I, Hansen H, Vilmann P, Jacobsen G, Backer V, Maltbaek N, Pedersen J, Madsen H, Nielsen H, Højgaard L: Preoperative Staging of Lung Cancer with Combined PET–CT. The New England journal of medicine 2009,361(1):32-39. 10.1056/NEJMoa0900043CrossRefPubMed

43.

Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E, Detterbeck F: Noninvasive Staging of Non-small Cell Lung Cancer: ACCP Evidenced-Based Clinical Practice Guidelines (2nd Edition). Chest 2007,132(3_suppl):178S-201S. 10.1378/chest.07-1360CrossRefPubMed

44.

Mac Manus MP, Hicks RJ: The role of positron emission tomography/computed tomography in radiation therapy planning for patients with lung cancer. Seminars in nuclear medicine 2012,42(5):308-319. 10.1053/j.semnuclmed.2012.04.003CrossRefPubMed

45.

Holloway CL, Robinson D, Murray B, Amanie J, Butts C, Smylie M, Chu K, McEwan AJ, Halperin R, Roa WH: Results of a phase I study to dose escalate using intensity modulated radiotherapy guided by combined PET/CT imaging with induction chemotherapy for patients with non-small cell lung cancer. Radiother Oncol 2004,73(3):285-7. 10.1016/j.radonc.2004.07.033CrossRefPubMed

46.

Marks LB, Munley MT, Spencer DP, Sherouse GW, Bentel GC, Hoppenworth J, Chew M, Jaszczak RJ, Coleman RE, Prosnitz LR: Quantification of radiation-induced regional lung injury with perfusion imaging. Int J Radiat Oncol Biol Phys 1997,38(2):399-409. 10.1016/S0360-3016(97)00013-8CrossRefPubMed

47.

Marks LB, Spencer DP, Bentel GC, Ray SK, Sherouse GW, Sontag MR, Coleman RE, Jaszczak RJ, Turkington TG, Tapson V: The utility of SPECT lung perfusion scans in minimizing and assessing the physiologic consequences of thoracic irradiation. Int J Radiat Oncol Biol Phys 1993,26(4):659-68. 10.1016/0360-3016(93)90285-4CrossRefPubMed

48.

Vinogradskiy Y, Castillo R, Castillo E, Tucker S, Zhongxing L, Guerrero T, Martel M: Using 4DCT-Based Ventilation Imaging to Correlate Lung Dose and Function with Clinical Outcomes. J Radiat Oncol Biol Phys 2013. in press

49.

Hope AJ, Lindsay PE, El Naqa I, Alaly JR, Vicic M, Bradley JD, Deasy JO: Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters. Int J Radiat Oncol Biol Phys 2006,65(1):112-124. 10.1016/j.ijrobp.2005.11.046CrossRefPubMed

50.

Bradley JD, Hope A, Naqa IE, Apte A, Lindsay PE, Bosch W, Matthews J, Sause W, Graham MV, Deasy JO: A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data. Int J Radiat Oncol Biol Phys 2007, 69: 984-995.CrossRef

51.

McCurdy M, McAleer MF, Wei W, Ezhil M, Johnson V, Khan M, Baker J, Luo D, Ajani J, Guerrero T: Induction and Concurrent Taxanes Enhance both the Pulmonary Metabolic Radiation Response and the Radiation Pneumonitis Response in Patients with Esophagus Cancer. Int J Radiat Oncol Biol Phys 2010,76(3):816-823. 10.1016/j.ijrobp.2009.02.059PubMedCentralCrossRefPubMed

52.

Khan A, McNally D, Tutschka PJ, Bilgrami S: Paclitaxel-induced acute bilateral pneumonitis. Ann Pharmacother 1997,31(12):1471-1474.PubMed

53.

Wong P, Leung AN, Berry GJ, Atkins KA, Montoya JG, Ruoss SJ, Stockdale FE: Paclitaxel-induced hypersensitivity pneumonitis: Radiographic and CT findings. Am J Roentgenol 2001,176(3):718-720. 10.2214/ajr.176.3.1760718CrossRef

54.

Schweitzer VG, Juillard GJF, Bajada CL, Parker RG: Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel. Cancer 1995,76(6):1069-1072. 10.1002/1097-0142(19950915)76:6<1069::AID-CNCR2820760623>3.0.CO;2-7CrossRefPubMed

55.

Machtay M, Bae K, Movsas B, Paulus R, Gore EM, Komaki R, Albain K, Sause WT, Curran WJ: Higher Biologically Effective Dose of Radiotherapy Is Associated With Improved Outcomes for Locally Advanced Non–Small Cell Lung Carcinoma Treated With Chemoradiation: An Analysis of the Radiation Therapy Oncology Group. International Journal of Radiation Oncology*Biology*Physics 2012,82(1):425-434. 10.1016/j.ijrobp.2010.09.004CrossRef

56.

Didierlaurent D, Ribes S, Caselles O, Jaudet C, Cazalet J-M, Batatia H, Courbon F: A new respiratory gating device to improve 4D PET/CT. Medical Physics 2013,40(3):32501–1-32501–9.CrossRef

57.

Barr JT, Schumacher GE, Freeman S, LeMoine M, Bakst AW, Jones PW: American translation, modification, and validation of the St. George's Respiratory Questionnaire. Clin Ther 2000,22(9):1121-1145.PubMed

Title: Pre-radiotherapy FDG PET predicts radiation pneumonitis in lung cancer
Authors: Richard Castillo
Ngoc Pham
Sobiya Ansari
Dmitriy Meshkov
Sarah Castillo
Min Li
Adenike Olanrewaju
Brian Hobbs
Edward Castillo
Thomas Guerrero
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Radiation Oncology / Issue 1/2014
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/1748-717X-9-74

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pre-radiotherapy FDG PET predicts radiation pneumonitis in lung cancer

Abstract

Background

Methods and Materials

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods and Materials

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Long-term outcomes of adjuvant radiotherapy after surgical resection of central neurocytoma

Dual-gated volumetric modulated arc therapy

Assessing the robustness of passive scattering proton therapy with regard to local recurrence in stage III non-small cell lung cancer: a secondary analysis of a phase II trial

The role of radiotherapy in the management of POEMS syndrome

Whole brain radiotherapy plus simultaneous in-field boost with image guided intensity-modulated radiotherapy for brain metastases of non-small cell lung cancer

No difference in dose distribution in organs at risk in postmastectomy radiotherapy with or without breast implant reconstruction